Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

PHASE3RecruitingINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2026

Conditions
Gestational Trophoblastic Neoplasms
Interventions
DRUG

Etoposide

etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle

DRUG

actinomycin D

actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle

DRUG

methotrexate

methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid (FA) 15mg q12h\*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle

DRUG

vincristine

vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle

DRUG

cyclophosphamide

cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle

DRUG

Paclitaxel

paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle

DRUG

Cisplatin

cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle

DRUG

Carboplatin

carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin

Trial Locations (1)

Unknown

RECRUITING

Weiguo Lv, Hangzhou

All Listed Sponsors
collaborator

Shandong University

OTHER

collaborator

Huazhong University of Science and Technology

OTHER

collaborator

First Affiliated Hospital of Zhongshan Medical University

OTHER

lead

Weiguo Lv

OTHER